UThymoKidney (Xenokidney)
End-Stage Renal Disease
Clinical (Expanded Access)Active (First living human transplant 2024)
Key Facts
Indication
End-Stage Renal Disease
Phase
Clinical (Expanded Access)
Status
Active (First living human transplant 2024)
Company
About United Therapeutics
Founded on a personal mission to treat pulmonary arterial hypertension, United Therapeutics has grown into a diversified, multi-platform biotech leader with a $26B+ market cap. The company successfully commercializes a portfolio of PAH therapies while aggressively pursuing its 'Mozart' moonshot to create an unlimited supply of transplantable organs. This dual strategy balances near-term financial strength from its rare disease franchise with transformative, long-term value creation in organ manufacturing and regenerative medicine.
View full company profileOther End-Stage Renal Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Inspirex™ Kidney | Xylyx Bio | Prototype |
| Bioprinted Kidney | Vital3D Technologies | Research |